Pfizer to allow generic versions of its COVID-19 pill in 95 countries

pfizer to allow generic versions of its covid 19 pill in 95 countries

Sumary of Pfizer to allow generic versions of its COVID-19 pill in 95 countries:

  • Pfizer Inc said on Tuesday it will allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low— and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP).
  • The voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified generic drug manufacturers to make their own versions of PF-07321332. Pfizer will sell the pills it manufactures under the brand name Paxlovid.
  • Pfizer, which also makes one of the mostly widely used COVID-19 vaccines, has said the pill cut the chance of hospitalization or death for adults at risk of severe disease by 89% in its clinical trial.
  • Pfizer’s licensing deal follows a similar arrangement by rival Merck &
  • “We are extremely pleased to have another weapon in our armory to protect people from the ravages of COVID-19,” Charles Gore, Executive Director of the Medicines Patent Pool, said in an interview.
  • Gore said he hoped the generic version of Pfizer’s drug will be available within months.
  • They also include countries that have transitioned from lower-middle to upper-middle-income status in the past five years, Pfizer and the MPP said.
  • “We believe oral antiviral treatments can play a vital role in reducing the severity of COVID-19 infections… We must work to ensure that all people — regardless of where they live or their circumstances — have access to these breakthroughs,” Pfizer Chief Executive Albert Bourla said in a statement.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close